The purpose of this clinical research study is to evaluate the safety and effectiveness of
an investigational medication to treat macular edema that persists despite current treatment
methods. Participants will be evaluated for improvement in vision and side effects.
Macular edema is a condition that affects the back of the eye (retina). It frequently
occurs in people who have a history of diabetes, and is also associated with high blood
pressure, uveitis, and previous eye surgery. The main symptom of macular edema is decreased
vision, generally a blurring of central vision.
There are no direct costs to participants for assessments and treatment as defined in the
study protocol. All candidates must be available for required scheduled visits during the
trial's 6-month follow-up period. Although the disease called age-related macular
degeneration (AMD) affects the same region of the eye as macular edema, they are not the
same condition and AMD is not studied in this research trial.
Inclusion: Persistent macular edema associated with diabetic retinopathy, uveitis, retinal
vein occlusion, or Irvine-Gass syndrome, persisting at least 90 days after laser treatment
or medical management by a physician.
Exclusion: Females who are pregnant or lactating, and females of childbearing potential
not using adequate birth control for the duration of the study. Any intraocular procedures
or laser treatment less than 90 days before enrollment.